- Lilly, with new data, to seek FDA approval of obesity drug retatrutideThe new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.BioPharma Dive · 5d ago↗ source
- Merck CEO cautions Congress on imposing limits on Chinese dealmakingMerck CEO Rob Davis said he has warned Congress and the Trump administration that if they cut off or hamper US-China dealmaking, the US could lose its status as the world's biotech leader. China-li…Endpoints · 5d ago↗ source
- Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drugScancell to merge into Neuphoria: Scancell plans to take over Neuphoria Therapeutics' Nasdaq listing {$NEUP} and change the ticker to SCLT. The company eyes up to $89 million in equity and ...